Stocktoria

Lantern Pharma Inc. LTRN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-06-11

Lantern Pharma Inc. statistics & valuation

Market cap$49.2M
P / B7.5×
Return on capital-275.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
2019202020212022202320242025
Return on equity (%)
-257.40% -30.00% -17.30% -25.40% -39.00% -98.10% -262.00% 2019202020212022202320242025
Shares outstanding
2.0M 6.2M 11.1M 10.9M 10.8M 10.8M 11.3M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-169.50% -29.00% -16.70% -24.20% -36.60% -81.30% -155.10% 2019202020212022202320242025
Free cash flow margin (%)
2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$1.31 -$1.47 -$1.93 -$1.57 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-155.1%-81.3%-36.6%-24.2%-16.7%-29.0%-169.5%
Return on equity-262.0%-98.1%-39.0%-25.4%-17.3%-30.0%-257.4%
Current ratio2.405.8316.1820.9931.2636.642.52

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.